Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QP-6211
- Development stage
- Phase 3
- Lead developer
- Nanjing Delova Biotech
- Modality
- Small Molecules
- Administration
- Injection
01
Overview
QP-6211 is an investigational analgesic drug developed by Nanjing Qingpu Biotechnology for the management of postoperative pain, particularly following hemorrhoidectomy. It is being evaluated for its efficacy, safety, and pharmacokinetic properties in clinical trials. The drug is administered via injection and has reached Phase 2/3 clinical development for postoperative pain indications. While the precise mechanism of action has not been publicly disclosed, it is classified as a small molecule analgesic intended to provide effective pain relief after surgical procedures[1][3][4].
Beyond the preview
Go deeper on QP-6211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QP-6211.